J B Chemicals and Pharmaceuticals Limited has announced the allotment of 31,160 equity shares under its Employee Stock Option Scheme (ESOP), marking another milestone in the company's employee incentive program. The pharmaceutical company disclosed this development to BSE Limited on February 19, 2026, in compliance with regulatory requirements.

ESOP Allotment Details

The Compensation Committee of the Board of Directors approved the allotment of 31,160 fully paid-up equity shares of Re. 1 each to one ESOP holder. The shares were allotted following the exercise of stock options granted under the JBCPL Employee Stock Option Scheme, 2021.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued, subscribed and paid-up capital. The share capital structure has been updated to reflect the new equity base following the ESOP exercise.

Regulatory Compliance

The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015. The communication was sent to BSE Limited, where the company's shares are listed under scrip code 506943 and stock symbol JBCHEPHARM. The disclosure also references the SEBI Master Circular bearing reference number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Information

J.B. Chemicals & Pharmaceuticals Limited operates with its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra. The company, incorporated with CIN L24390GJ1976PLC173077, continues to execute its employee stock option schemes as part of its human resource strategy. The allotment was communicated by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, ensuring proper regulatory compliance and transparency.

J B Chemicals and Pharmaceuticals Limited has announced a key change in its senior management with the resignation of Mr. Himanshu Ranvah from his position as Vice President-Legal. The pharmaceutical company disclosed this development in compliance with regulatory requirements under SEBI listing obligations.

Resignation Details

Mr. Himanshu Ranvah ceased to be the Vice President-Legal with effect from closing of business hours on February 6, 2026. The company formally communicated this change to BSE Limited through a regulatory filing dated February 7, 2026.

Resignation Letter Highlights

In his resignation letter dated January 23, 2026, addressed to Chief Financial Officer Narayan Saraf, Mr. Ranvah expressed his decision to step down after careful consideration. He acknowledged his tenure with the company as an incredible journey and tremendous learning opportunity that he would cherish forever.

Transition Arrangements

To ensure operational continuity, Mr. Ranvah committed to a smooth handover of his work and responsibilities to Mr. Vishal Chavan. The outgoing Vice President-Legal requested to be relieved at the earliest while ensuring proper knowledge transfer.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, in conjunction with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary.

J.B. Chemicals & Pharmaceuticals Limited, incorporated in 1976 with CIN L24390GJ1976PLC173077, operates from its corporate office in Mumbai's Prabhadevi area while maintaining its registered office in Ahmedabad, Gujarat.